Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $60
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Corbus Pharmaceuticals (CRBP) Receives a Buy From Mizuho Securities
Express News | Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Expected in Q1 2025
Express News | Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (Crb-701)
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit
Cannabis Stock Movers For September 25, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Corbus Pharmaceuticals(CRBP.US) 10% Shareholder Buys US$7 Million in Common Stock
$Corbus Pharmaceuticals(CRBP.US)$ 10% Shareholder Cormorant Asset Management, LP purchased 350K shares of common stock on Sep 20, 2024 at an average price of $20.011 for a total value of $7 million.
Cormorant Asset Management Buys $7m in Corbus Pharmaceuticals Stock
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $74
Mizuho Securities analyst Graig Suvannavejh maintains $Corbus Pharmaceuticals(CRBP.US)$ with a buy rating, and sets the target price at $74.According to TipRanks data, the analyst has a success rate
Mizuho Recommends Buying Corbus Following Its Drop Post-Novo's Obesity Data
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright analyst Andres Y. Maldonado maintains $Corbus Pharmaceuticals(CRBP.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Corbus Pharmaceuticals on CRB-913's Potential and Holistic Pipeline Valuation
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target